P11.03: Ultrasound features of ovarian carcinoma in patients with BRCA 1 or BRCA 2 mutation
نویسندگان
چکیده
منابع مشابه
BRCA 1, BRCA 2 models.
Anticipating that genetic tests designed to determine an individuals predisposition to disease would eventually become commercially available, and recognizing that the results of many of these tests may have mortality implications, in 1994 Lincoln National Reinsurance Companies began developing a methodology that would allow the mortality risk associated with a number of different genetic mutat...
متن کاملCarcinogenesis and Effect of BRCA-1 and BRCA-2 Mutation on Breast Cancer Development
Cancer is the most important factor of death after cardiovascular diseases in human populations. So, the reserachers consider cancer as a factor of 13% of deaths that occur in the world. However, breast cancer is the most common type of cancer in women. Statistics show that the number of patients referred to America's Breast Cancer Clinic increased from 3745 in 2003 to 6671 in 2009 and cases of...
متن کاملBRCA-1 and BRCA-2 mutation bedside detection and breast cancer clinical primary prevention
As regards the interesting discovery of a novel BRCA1 mutation in a family of Palestinian Arabian origin (Kadouri et al., 2007), we would like to state that all gene mutations bring about necessarily local biological activity modification, otherwise, gene mutations would be meaningless innocent bystanders (Stagnaro-Neri and Stagnaro, 1995; Kadouri et al., 2007; Stagnaro, 2008). In the present a...
متن کاملBeyond Breast and Ovarian Cancers: PARP Inhibitors for BRCA Mutation-Associated and BRCA-Like Solid Tumors
Poly(ADP-ribose) polymerase inhibitors (PARPi) have shown clinical activity in patients with germline BRCA1/2 mutation (gBRCAm)-associated breast and ovarian cancers. Accumulating evidence suggests that PARPi may have a wider application in the treatment of cancers defective in DNA damage repair pathways, such as prostate, lung, endometrial, and pancreatic cancers. Several PARPi are currently i...
متن کاملHereditary Ovarian Cancer: Not Only BRCA 1 and 2 Genes
More than one-fifth of ovarian tumors have hereditary susceptibility and, in about 65-85% of these cases, the genetic abnormality is a germline mutation in BRCA genes. Nevertheless, several other suppressor genes and oncogenes have been associated with hereditary ovarian cancers, including the mismatch repair (MMR) genes in Lynch syndrome, the tumor suppressor gene, TP53, in the Li-Fraumeni syn...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: Ultrasound in Obstetrics & Gynecology
سال: 2017
ISSN: 0960-7692
DOI: 10.1002/uog.18103